R & D

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

 This material is intended to notify the press release issued on September 15 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.